Monica M. Holden
Biography
Overview
Monica Holden is a partner based in London. She has experience advising on a broad range of global transactions, including public and private equity and debt offerings (high yield bonds, investment grade bonds, initial public offerings, SEC-registered offerings, private placements and USPP transactions) and mergers and acquisitions across a number of jurisdictions. Monica regularly advises US public companies, and is an expert in US securities law issues related to mergers and acquisitions, including cross border tender offer rules and securities exemptions.
Experience
Advising Arqit Quantum Inc. in connection with its SEC-registered public offerings, ongoing U.S. public company advice and initial public listing on NASDAQ.
Advising a publicly-traded international specialty chemicals company on its debut offering of US$1.2 billion in investment grade bonds.
Advising the offeror on U.S. securities laws in connection with its offer to acquire all of the outstanding share capital of a U.K. PLC.
Advising the managers in connection with multiple issuances by Digital Realty of investment grade senior unsecured notes denominated in EUR and GBP.
Advising Encore Capital Group, Inc. in connection with the issuance of US$500 million in 9.250% notes due 2029 and US$500 million in 8.500% notes due 2030.
Advising Encore Capital Group, Inc. in connection with the implementation of its US$1.5 billion global funding structure, including the issuance of new senior secured notes, the consent solicitation of the holders of two existing senior secured notes issuances, the amendment and restatement of its USPP agreement and an amended multi-currency revolving credit facility.
Advising Arabian Centres Company on its issuance of US$600 million trust certificates due 2029.
Advising Kornit Digital Ltd. on its SEC-registered underwritten public offering raising net proceeds of US$341 million for Kornit and US$103 million for an affiliate of Amazon.com, Inc.
Advising Kobalt Music Group Limited on its agreement to divest its recorded music operations to Sony Music Entertainment.
Advising Takeda in connection with its agreements to divest portfolios of select pharmaceutical assets to:
- Hasten Biopharmaceutic Co. Ltd. for approximately US$322 million;
- Cheplapharm for approximately US$562 million;
- Celltrion for up to $278 million;
- Orifarm Group for approximately $670 million;
- Hypera Pharma for a total value of US$825 million;
- STADA Arzneimittel AG for a total value of $660 million; and
- Acino for a total value in excess of $200 million.
